Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ad-A-p50
- Development stage
- Preclinical
- Lead developer
- Duke University
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, Gene Silencing → Gene Therapies, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics, Gene Editing → Gene Therapies, Gene Addition/Replacement → Gene Therapies
- Administration
- Intratumoral
01
Overview
Ad-A-p50 is a preclinical adenoviral gene therapy vector designed to deliver an RNA aptamer (A-p50) that specifically binds to and inhibits the p50 subunit of nuclear factor-kappaB (NF-kappaB). Developed for the treatment of advanced non-small cell lung cancer (NSCLC), it aims to overcome chemoresistance to agents like doxorubicin. By blocking NF-kappaB activation, Ad-A-p50 modulates the expression of genes involved in cell proliferation (Ki-67), DNA damage response (GADD153), and anti-apoptosis (Bcl-XL). It also interferes with angiogenesis by inhibiting the HIF-1alpha/VEGF pathway.
- Other names
- Ad-Aptamer-p50Ad-Aptamer-p-50Ad-Aptamer-p 50adenoviral RNA aptamer p50
02
Targets
NFKB1 (NF-κB1)
Beyond the preview
Go deeper on Ad-A-p50.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ad-A-p50.